Pandorum Technologies, a biotechnology company focused on programmable regenerative medicine, has raised $18 million in a Series B funding round to advance clinical development and expand global operations.The round was led by Protons Corporate, with participation from Galentic Pharma, investor Ashish Kacholia, Noblevast Advisory and Avinya Fund, the Burman Family, and others. Bandana Kankani, advisor and investor at Pandorum, guided the transaction.The Bengaluru-based company, which operates in India and the United States, said the financing will support the development of therapies and help scale manufacturing across the US, Japan, and the Middle East.Founded by Tuhin Bhowmick and Arun Chandru, Pandorum Technologies is a tissue engineering and regenerative medicine company that designs therapeutic products that aim to alleviate the health conditions of patient’s suffering from on corneal dystrophies, lung-related disorders, and liver diseases.The company has adopted a distributed manufacturing strategy. It has partnered with AGC Biologics in Italy to serve the US and European markets and is collaborating with Nucelion Therapeutics, a subsidiary of Bharat Biotech in India, to support supply across Asia-Pacific. It is also exploring potential partnerships in the Middle East.Also ReadVelocity commits Rs 100 Cr to expand AI-led shipping platformPandorum’s lead focus is on ocular surface diseases, including… Read MoreYourStory RSS Feed
